<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>IMOVAX <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">RABIES</span>- <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> virus <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> pm-1503-3m antigen (propiolactone inactivated) and water 
			 </strong><br>Sanofi Pasteur Inc.<br></p></div>
<h1><span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> Vaccine<br> IMOVAX<span class="Sup">®</span> <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">RABIES</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold Italics">Rx only</span></p>
<p><span class="Bold">WISTAR <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">RABIES</span> VIRUS <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">STRAIN</span> PM-1503-3M<br>GROWN IN HUMAN DIPLOID CELL CULTURES</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="description"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">The Imovax<span class="Sup">®</span> <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> Vaccine produced by Sanofi Pasteur SA is a sterile, stable, freeze-dried suspension of <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> virus prepared from <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> PM-1503-3M obtained from the Wistar Institute, Philadelphia, PA.</p>
<p>The virus is harvested from infected human diploid cells, MRC-5 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>, concentrated by ultrafiltration and is inactivated by beta-propiolactone. One dose of reconstituted vaccine contains less than 100 mg human albumin, less than 150 mcg neomycin sulfate and 20 mcg of phenol red indicator. Beta-propiolactone, a residual component of the manufacturing process, is present in less than 50 parts per million.</p>
<p>The finished, freeze-dried vaccine is provided for intramuscular administration in a single dose vial containing no preservative. After reconstitution, immediately administer the full 1.0 mL amount of vaccine. If it cannot be administered promptly, discard.</p>
<p>The potency of one dose (1.0 mL) of Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine is equal to or greater than 2.5 international units of <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> antigen.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>Pre-exposure immunization</h2>
<p class="First">High titer antibody responses to the Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine made in human diploid cells have been demonstrated in trials conducted in England (1), Germany (2) (3), France (4) and Belgium. (5) Seroconversion was often obtained with only one dose. With two doses one month apart, 100% of the recipients developed specific antibody, and the geometric mean titer of the group was approximately 10 international units. In the US, Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine resulted in geometric mean titers (GMT) of 12.9 IU/mL at Day 49 and 5.1 IU/mL at Day 90 when three doses were given intramuscularly during the course of one month. The range of antibody responses was 2.8 to 55.0 IU/mL at Day 49 and 1.8 to 12.4 IU at Day 90. (6) The definition of a minimally accepted antibody titer varies among laboratories and is influenced by the type of test conducted. CDC currently specifies a 1:5 titer (complete inhibition) by the rapid fluorescent focus inhibition test (RFFIT) as acceptable. The World Health Organization (WHO) specifies a titer of 0.5 IU.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Post-exposure immunization</h2>
<p class="First">Post-exposure efficacy of Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine was successfully proven during clinical experience in Iran in which six 1.0 mL doses were given on days 0, 3, 7, 14, 30, and 90, in conjunction with antirabies serum. Forty-five persons severely bitten by rabid dogs and wolves received Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine within hours of and up to 14 days after the bites. All individuals were fully protected against <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span>. (7)</p>
<p>Studies conducted by the United States Centers for Disease Control and Prevention (CDC) have shown that a regimen of 1 dose of <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> Immune Globulin (RIG) and 5 doses of HDCV induced an excellent antibody response in all recipients. Of 511 persons bitten by proven rabid animals and so treated, none developed <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span>. (8) </p>
<p>Do not inject Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine in the gluteal area as there have been reports of possible vaccine failure when the vaccine has been administered in this area. Presumably, subcutaneous fat in the gluteal area may interfere with the immune response to human diploid cell <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> vaccine (HDCV).  (9) (10) </p>
<p>For adults and older children, Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine should be administered in the deltoid muscle. For infants and younger children, the anterolateral aspect of the thigh is also acceptable, depending on age and body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> (see<a href="#DAA"> DOSAGE AND ADMINISTRATION</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> is a vaccine indicated for pre-exposure and post-exposure prophylaxis against <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span>. Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine is approved for use in all age groups.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>1. Rationale of treatment</h2>
<p class="First">Physicians must evaluate each possible <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> exposure. Local or state public health officials should be consulted if questions arise about the need for prophylaxis. (11) </p>
<p>The following factors should be considered before antirabies prophylaxis is initiated.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.1"></a><p></p>
<h3>Species of biting animal</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.1.1"></a><p></p>
<h4>Bats</h4>
<p class="First"> Rabid bats have been documented in the 49 continental states, and bats are increasingly implicated as important wildlife reservoirs for variants of <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> virus transmitted to humans. Transmission of <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> virus can occur from minor, seemingly underappreciated or unrecognized bites from bats (see<a href="#table2"> Table 2</a>). (11)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.1.2"></a><p></p>
<h4>Wild Terrestrial Carnivores</h4>
<p class="First">Raccoons, skunks, and foxes are the terrestrial carnivores most often infected with <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> in the United States. Suggestive clinical signs of <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> among wildlife cannot be interpreted reliably. All bites by such wildlife should be considered possible exposures to <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> virus. Post-exposure prophylaxis should be initiated as soon as possible following exposure to such wildlife, unless the animal is available for diagnosis and public health authorities are facilitating expeditious laboratory testing, or if the brain tissue from the animal has already tested negative (see<a href="#table2"> Table 2</a>). (11)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.1.3"></a><p></p>
<h4>Other Wild Animals</h4>
<p class="First">Small rodents (eg, squirrels, chipmunks, rats, mice, hamsters, guinea pigs, and gerbils) and lagomorphs (including rabbits and hares) are rarely infected with <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> and have not been known to transmit <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> to humans. In all cases involving rodents, the state or local health department should be consulted before a decision is made to initiate post-exposure prophylaxis (see<a href="#table2"> Table 2</a>). (11)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.1.4"></a><p></p>
<h4>Domestic Dogs, Cats, and Ferrets</h4>
<p class="First">The likelihood of <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> in a domestic animal varies regionally, and the need for post-exposure prophylaxis also varies on the basis of regional epidemiology (see<a href="#table2"> Table 2</a>). (11)</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.2"></a><p></p>
<h3>Circumstances of biting incident</h3>
<p class="First">An unprovoked attack might be more likely than a provoked attack to indicate the animal is rabid. Bites inflicted on a person attempting to feed or handle an apparently healthy animal should generally be regarded as provoked. Consult the local or state health department following a provoked or unprovoked exposure to determine the best course of action based on current public health recommendations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.3"></a><p></p>
<h3>Type of exposure</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> is transmitted by introducing the virus into open cuts or <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> in skin or via mucous membranes. The likelihood of <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> varies with the nature and extent of exposure. Two categories of exposure should be considered, bite and nonbite.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.3.1"></a><p></p>
<h4>Bite</h4>
<p class="First">Any penetration of the skin by teeth.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.3.2"></a><p></p>
<h4>Nonbite</h4>
<p class="First">Scratches, <span class="product-label-link" type="condition" conceptid="4269361" conceptname="Friction burn">abrasions</span>, open <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>, or mucous membranes contaminated with saliva or other potentially infectious material, such as brain tissue, from a rabid animal. Casual contact, such as petting a rabid animal, (without a bite or nonbite exposure as described above), does not constitute an exposure and is not an indication for prophylaxis. Rare reports of airborne <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> have been received from laboratory and bat-infested cave settings. (11)</p>
<p>Rare cases of <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> from human-to-human transmission have occurred in patients in the US and overseas who received organs transplanted from persons who died of <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> undiagnosed at the time of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. No documented laboratory-diagnosed cases of human-to-human <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> transmission have been documented from a bite or nonbite exposure other than the transplant cases. At least two cases of human-to-human <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> transmission in Ethiopia have been suggested, but <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> as the cause of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was not confirmed by laboratory testing. The reported route of exposure in both cases was direct salivary contact from another human (ie, a bite and a kiss). Routine delivery of health care to a patient with <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> is not an indication for post-exposure prophylaxis unless the healthcare worker is reasonably certain that he or she was bitten by the patient or that his or her mucous membranes or nonintact skin was exposed directly to potentially infectious saliva or neural tissue. (11)</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>2. Pre- and post-exposure prophylaxis of <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.1"></a><p></p>
<h3>A. Pre-exposure </h3>
<p class="First">Pre-exposure immunization should be offered to <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> researchers, certain laboratory workers and other persons in high-risk groups, such as veterinarians and their staff, and animal handlers. Pre-exposure vaccination also should be considered for persons whose activities bring them into frequent contact with <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> virus or potentially rabid bats, raccoons, skunks, cats, dogs, or other species at risk for having <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span>. In addition, some international travelers might be candidates for pre-exposure vaccination if they are likely to come in contact with animals in areas where dog or other animal <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> is enzootic and immediate access to appropriate medical care, including <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> vaccine and immune globulin, might be limited. (11)</p>
<p>Vaccination is recommended for children living in or visiting countries where exposure to rabid animals is a constant threat. Worldwide statistics indicate children are more at risk than adults.</p>
<p>Pre-exposure prophylaxis is administered for several reasons. First, although pre-exposure vaccination does not eliminate the need for additional medical evaluation after a <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> exposure, it simplifies management by eliminating the need for <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> Immune Globulin (RIG) and decreases the number of doses of vaccine needed. This is particularly important for persons at high risk for being exposed to <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> in areas where modern immunizing products might not be available or where cruder, less safe biologics might be used, placing the exposed person at increased risk for adverse events. Second, pre-exposure prophylaxis might offer partial immunity to persons whose post-exposure prophylaxis is delayed. Finally, pre-exposure prophylaxis might provide some protection to persons at risk for unrecognized exposures to <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span>. (11)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.1.1"></a><p></p>
<h4>PRE-EXPOSURE <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">RABIES</span> PROPHYLAXIS GUIDE</h4>
<p class="First">Pre-exposure prophylaxis consists of three 1.0 mL doses of Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine administered intramuscularly, using a sterile needle and syringe, one injection per day on Days 0, 7, and 21 or 28. In adults and older children, the vaccine should be administered in the deltoid muscle. In infants and small children, the anterolateral aspect of the thigh may be preferable, depending on age and body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>.</p>
<p>Administration of booster doses of vaccine depends on exposure risk category and serologic testing as noted in Table 1.</p>
<p>Immunosuppressed persons should postpone pre-exposure vaccinations and consider avoiding activities for which <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> pre-exposure prophylaxis is indicated. When this course is not possible, immunosuppressed persons who are at risk for <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> should have their viral neutralizing antibody titers checked after completing the pre-exposure series. If no acceptable antibody response is detected, the patient should be managed in consultation with their physician and appropriate public health officials. (11)</p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1: <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> Pre-exposure Prophylaxis Guide (11)</span></caption>
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Risk category</th>
<th class="Rrule" align="center">Nature of risk</th>
<th class="Rrule" align="left">Typical populations</th>
<th class="Rrule" align="center">Pre-exposure recommendations</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Minimum acceptable antibody level is complete virus neutralization at a 1:5 serum dilution by the rapid fluorescent focus inhibition test. A booster dose should be administered if the titer <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below this level.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Continuous</span></td>
<td class="Rrule" align="left">Virus present continuously and often in high concentrations. Specific exposures likely to go unrecognized. Bite, nonbite, or aerosol exposure.  </td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> research laboratory workers; <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> biologics production workers.</td>
<td class="Rrule" align="left">Primary course. Serologic testing every 6 months; booster vaccination if antibody titer is below acceptable level.<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Frequent</span></td>
<td class="Rrule" align="left">Exposure usually episodic, with source recognized, but exposure also might be unrecognized. Bite, nonbite, or aerosol exposure.</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> diagnostic laboratory workers, cavers, veterinarians and staff, and animal-control and wildlife workers in areas where <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> is enzootic. All persons who frequently handle bats.</td>
<td class="Rrule" align="left">Primary course. Serologic testing every 2 years; booster vaccination if antibody titer is below acceptable level.<a href="#footnote-1" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Infrequent (greater than population at large)</span></td>
<td class="Rrule" align="left">Exposure nearly always episodic with source recognized. Bite or nonbite exposure.</td>
<td class="Rrule" align="left">Veterinarians and animal-control staff working with terrestrial animals in areas where <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> is uncommon to rare. Veterinary students. Travelers visiting areas where <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> is enzootic and immediate access to appropriate medical care including biologics is limited.</td>
<td class="Rrule" align="left">Primary course. No serologic testing or  booster vaccination.</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">Rare (population at large)</span></td>
<td class="Rrule" align="left">Exposure always episodic with source recognized. Bite or nonbite exposure.</td>
<td class="Rrule" align="left">US population at large, including persons in areas where <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> is epizootic. </td>
<td class="Rrule" align="left">No vaccination necessary.</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.2"></a><p></p>
<h3>B. Post-exposure </h3>
<p class="First">The essential components of <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> post-exposure prophylaxis are <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> treatment and, for previously unvaccinated persons, the administration of both human <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> immune globulin (RIG) and vaccine. (11)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.2.1"></a><p></p>
<h4>1. Local treatment of <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span></h4>
<p class="First">Thorough washing and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> (for about 15 minutes, if possible) with soap or a cleansing agent and copious amounts of water of all bite <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> and scratches should be done immediately or as early as possible. Where available, an iodine-containing, or similarly viricidal, topical preparation should be applied to the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span>. (12)</p>
<p><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> prophylaxis and measures to control <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> should be given as indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.2.2"></a><p></p>
<h4>2. Specific treatment</h4>
<p class="First">The sooner treatment is begun after exposure, the better. Post-exposure antirabies vaccination should always include administration of both passive antibody and vaccine, with the exception of persons who have ever previously received complete vaccination regimens (pre-exposure or post-exposure) with a cell culture vaccine or persons who have been vaccinated with other types of vaccines and have previously had a documented <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> virus neutralizing antibody titer. These persons should receive only vaccine (ie, post-exposure for a person previously vaccinated). The combination of RIG and vaccine is recommended for both bite and nonbite exposures reported by persons who have never been previously vaccinated for <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span>, regardless of the interval between exposure and initiation of prophylaxis. If post-exposure prophylaxis has been initiated and appropriate laboratory diagnostic testing (ie, the direct fluorescent antibody test) indicates that the exposing animal was not rabid, post-exposure prophylaxis can be discontinued. (11)  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.2.3"></a><p></p>
<h4>3. Treatment outside the United States</h4>
<p class="First">If post-exposure is begun outside the United States with locally produced biologics, it may be desirable to provide additional treatment when the patient reaches the US. State or local health departments should be contacted for specific advice in such cases. (11)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.2.4"></a><p></p>
<h4>POST-EXPOSURE <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">RABIES</span> PROPHYLAXIS GUIDE</h4>
<p class="First">The following recommendations are only a guide. In applying them, take into account the animal species involved, the circumstances of the bite or other exposure, the vaccination status of the animal, the availability of the exposing animal for observation or <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> testing, and the presence of <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> in the region (see<a href="#table2"> Table 2</a>). Local or state public health officials should be consulted if questions arise about the need for <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> prophylaxis. (11)</p>
<a name="table2"></a><table width="100%">
<caption><span>Table 2: Post-exposure Treatments Guide (11)</span></caption>
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="34%">
<col align="left" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Animal type</th>
<th class="Rrule" align="center">Evaluation and disposition of animal</th>
<th class="Rrule" align="center">Post-exposure prophylaxis recommendations</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>During the 10-day observation period, begin post-exposure prophylaxis at the first sign of <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> in a dog, cat, or ferret that has bitten someone. If the animal exhibits clinical signs of <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span>, it should be euthanized immediately and tested.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>Post-exposure prophylaxis should be initiated as soon as possible following exposure to such wildlife unless the animal is available for testing and public health authorities are facilitating expeditous laboratory testing or it is already known that brain material from the animal has tested negative. Other factors that might influence the urgency of decision-making regarding initiation of post-exposure prophylaxis before diagnostic results are known include the species of the animal, the general appearance and behavior of the animal, whether the encounter was provoked by the presence of a human, and the severity and location of bites. Discontinue vaccine if appropriate laboratory diagnostic test (ie, the direct fluorescent antibody test) is negative.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">‡</a></dt>
<dd>The animal should be euthanized and tested as soon as possible. Holding for observation is not recommended.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">Dogs, cats, and ferrets</td>
<td class="Rrule" align="left">Healthy and available for 10 days observation.</td>
<td class="Rrule" align="left">Persons should not begin prophylaxis unless animal develops clinical signs of <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span>.<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left">Rabid or suspected rabid.</td>
<td class="Rrule" align="left">Immediately begin prophylaxis.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left">Unknown (eg, escaped).</td>
<td class="Rrule" align="left">Consult public health officials. </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Skunks, raccoons, foxes, and most other carnivores; bats<a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a>
</td>
<td class="Rrule" align="left">Regard as rabid unless animal proven negative by laboratory tests.<a name="footnote-reference-4" href="#footnote-4" class="Sup">‡</a>
</td>
<td class="Rrule" align="left">Consider immediate prophylaxis.</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Livestock, small rodents (rabbits and hares), large rodents (woodchucks and beavers), and other mammals</td>
<td class="Rrule" align="left">Consider individually. </td>
<td class="Rrule" align="left">Consult public health officials. Bites from squirrels, hamsters, guinea pigs, gerbils, chipmunks, rats, mice, other small rodents, rabbits, and hares almost never require anti-<span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> post-exposure prophylaxis.</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contraindications"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>Pre-exposure Prophylaxis</h2>
<p class="First">Do not administer to anyone with a known life-threatening systemic <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to any component of the vaccine (see<a href="#warnings"> WARNINGS</a>,<a href="#precautions"> PRECAUTIONS</a>, and<a href="#description"> DESCRIPTION </a>sections).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>Post-exposure Prophylaxis</h2>
<p class="First">None.</p>
</div>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<ul class="Disc">
<li>Do not inject the vaccine into the gluteal area as administration in this area may result in lower neutralizing antibody titers. (11) </li>
<li>The product is provided in a single dose vial. Because the single dose vial contains no preservative, it is not to be used as a multidose vial for intradermal injection. </li>
<li>In both pre-exposure and post-exposure immunization, the full 1.0 mL dose should be given intramuscularly.</li>
<li><span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">Serum sickness</span> type reactions have been reported in persons receiving booster doses of <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> vaccine for pre-exposure prophylaxis. The reaction is characterized by onset approximately 2 to 21 days post-booster, presents with a <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">generalized urticaria</span>, and may also include <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>. None of the reported reactions were life-threatening. This has been reported in up to 7% of persons receiving booster vaccination. (13) </li>
<li>Rare cases of neurologic illness resembling Guillain-Barré syndrome, (14) (15) a transient neuroparalytic illness, that resolved without sequelae in 12 weeks and a focal subacute <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">central nervous system disorder</span> temporally associated with HDCV, have been reported. (16)</li>
<li>This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.</li>
</ul>
<p class="First">All serious systemic neuroparalytic or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to a <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> vaccine should be immediately reported to VAERS at 1-800-822-7967 (http://vaers.hhs.gov) or Sanofi Pasteur Inc., 1-800-VACCINE (1-800-822-2463).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precautions"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<ul class="Disc">
<li>IN ADULTS AND CHILDREN THE VACCINE SHOULD BE INJECTED INTO THE DELTOID MUSCLE. IN INFANTS AND SMALL CHILDREN, THE ANTEROLATERAL ASPECT OF THE THIGH MAY BE PREFERABLE.</li>
<li>When a person with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> must be given <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> vaccine, antihistamines may be given. Epinephrine (1:1000) and other appropriate agents should be readily available to counteract <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, and the person should be carefully observed after immunization.</li>
<li>While the concentration of antibiotics in each dose of vaccine is extremely small, persons with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of these agents, or any other component of the vaccine, could manifest an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. While the risk is small, it should be weighed in light of the potential risk of contracting <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span>.</li>
</ul>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.1"></a><p></p>
<h2>DRUG INTERACTIONS</h2>
<p class="First">Corticosteroids, other immunosuppressive agents or treatments, and immunosuppressive illnesses can interfere with the development of active immunity and predispose the patient to developing <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span>. Immunosuppressive agents should not be administered during post-exposure therapy, unless essential for the treatment of other conditions. When <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> post-exposure prophylaxis is administered to persons receiving steroids or other immunosuppressive therapy, it is especially important that serum be tested for <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> antibody to ensure that an adequate response has developed. (11)</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.2"></a><p></p>
<h2>USAGE IN PREGNANCY</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.1"></a><p></p>
<h3>Pre-exposure</h3>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.2.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Animal reproduction studies have not been conducted with Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine. It is also not known whether Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine should be given to a pregnant woman only if potential benefits outweigh potential risks. If there is substantial risk of exposure to <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span>, pre-exposure prophylaxis may also be indicated during pregnancy. (11)</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.2"></a><p></p>
<h3>Post-exposure</h3>
<p class="First">Because of the potential consequences of inadequately treated <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> exposure and limited data that indicate that fetal abnormalities have not been associated with <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> vaccination, pregnancy is not considered a contraindication to post-exposure prophylaxis. (11) (17) </p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.3"></a><p></p>
<h2>USAGE IN NURSING MOTHERS</h2>
<p class="First">It is not known whether Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.4"></a><p></p>
<h2>PEDIATRIC USE</h2>
<p class="First">Both safety and efficacy in children have been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<ul class="Disc">
<li>Once initiated, <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> prophylaxis should not be interrupted or discontinued because of local or mild systemic adverse reactions to <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> vaccine. Usually such reactions can be successfully managed with anti-inflammatory, antihistaminic, and antipyretic agents. (11)</li>
<li>Reactions after vaccination with HDCV have been observed. (13)  In a study using five doses of HDCV, local reactions such as <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> at the injection site were reported in about 25% of recipients of HDCV, and mild systemic reactions such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> were reported in about 20% of recipients. (8) </li>
<li>Serious systemic anaphylactic or neuroparalytic reactions occurring during the administration of <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> vaccines pose a dilemma for the attending physician. A patient's risk of developing <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> must be carefully considered before deciding to discontinue vaccination. Moreover, the use of corticosteroids to treat life-threatening neuroparalytic reactions carries the risk of inhibiting the development of active immunity to <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span>. It is especially important in these cases that the serum of the patient be tested for <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> antibodies. Advice and assistance on the management of serious adverse reactions in persons receiving <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> vaccines may be sought from the local or state health department. (8)</li>
<li>SEE<a href="#warnings"> WARNINGS </a>AND<a href="#contraindications"> CONTRAINDICATIONS </a>SECTIONS FOR ADDITIONAL STATEMENTS.</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Data from post-marketing experience</h2>
<p class="First">The following additional adverse events have been identified during postapproval use of Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine exposure.</p>
<p><span class="Italics">Blood and Lymphatic System Disorders</span></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span></dd>
</dl>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span> type reaction, <span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">dermatitis allergic</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (<span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>), <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></dd>
</dl>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="378143" conceptname="Encephalitis">encephalitis</span></dd>
</dl>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
</dl>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></dd>
</dl>
<p><span class="Italics">General Disorders and Administration Site Conditions</span></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> (<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span>), injection site <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span></dd>
</dl>
<p><span class="Italics">Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">Wheezing</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DAA"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Parenteral drug products should be inspected for particulate matter and discoloration prior to administration, whenever solution and container permit. The syringe and its package should also be inspected prior to use for evidence of leakage, premature activation of the plunger, or a faulty tip seal. If evidence of such defects is observed, the product should not be used.</p>
<p>The package contains a vial of freeze-dried vaccine, a syringe containing 1.0 mL of diluent, a plunger for the syringe, and a sterile needle for reconstitution. Cleanse the vaccine vial stopper with a suitable germicide. Do not remove the stopper or the metal seal holding it in place. Attach the plunger and reconstitution needle to the syringe and reconstitute the freeze-dried vaccine by injecting the diluent into the vaccine vial. Gently swirl the contents until completely dissolved and withdraw the total contents of the vial into the syringe. Remove the reconstitution needle and discard. Attach a sterile needle of your choice that is suitable for intramuscular injection of your patient.</p>
<p>The supplied syringe is intended for single use only, must not be reused, and must be disposed of properly and promptly following its use. </p>
<p>To help avoid transmission of infectious diseases due to accidental needle sticks, needles should not be recapped but disposed of according to recommended guidelines.</p>
<p>The reconstituted vaccine should not be mixed with any other vaccine and should be used immediately.</p>
<p>After preparation of the injection site with an appropriate germicide, immediately inject the vaccine intramuscularly. For adults and older children, the vaccine should be injected into the deltoid muscle. (10) (18) (19)  In infants and small children, the anterolateral aspect of the thigh may be preferable, depending on age and body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>. Care should be taken to avoid injection into or near blood vessels and nerves. If blood or any suspicious discoloration appears in the syringe, do not inject but discard contents and repeat procedure using a new dose of vaccine at a different site.</p>
<p>The gluteal area should not be used for administration of the vaccine as administration in this area may result in lower neutralizing antibody titers. (11)</p>
<p><span class="Bold">NOTE: </span>The freeze-dried vaccine is creamy white to orange. After reconstitution, it is pink to red.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>A. Pre-exposure dosage</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1.1"></a><p></p>
<h3>1. Primary vaccination</h3>
<p class="First">In the United States, the Immunization Practices Advisory Committee (ACIP) recommends three injections of 1.0 mL each, one injection on Day 0, one on Day 7, and one either on Day 21 or 28. (11) </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1.2"></a><p></p>
<h3>2. Booster dose</h3>
<p class="First">A booster dose consists of one injection of 1.0 mL of Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine. To ensure the presence of a primed immune response over time among persons at higher than normal risk for exposure, titers should be checked periodically, with booster doses administered only as needed. Persons working with live <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> virus in research laboratories and in vaccine production facilities (continuous risk category) should have <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> antibody titers checked every six months and boosters given as needed to maintain an adequate titer defined as virus neutralization at a 1:5 dilution by a RFFIT. Other laboratory workers (eg, those performing <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> diagnostic testing), cavers, veterinarians and staff, animal-control and wildlife officers in areas where <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> is enzootic, and bat handlers regardless of location, (frequent risk category), should have their serum tested for <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> antibody every 2 years. If their titer is inadequate, they should receive a single booster dose of vaccine. Veterinarians, veterinary students, and terrestrial animal-control and wildlife officers, working in areas of low <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> endemicity (infrequent risk category) and certain at-risk international travelers who have completed a full pre-exposure vaccination series with licensed vaccines and according to schedule do not require routine booster serologic verification of detectable antibody titers or routine pre-exposure booster doses of vaccine (see<a href="#table1"> Table 1</a>). (11) </p>
<p>Persons who have experienced "immune complex-like" <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> should receive no further doses of Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine unless they are exposed to <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> or they are truly likely to be inapparently and/or unavoidably exposed to <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> virus and have unsatisfactory antibody titers.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>B. Post-exposure dosage</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2.1"></a><p></p>
<h3>1. Post-exposure dosage for previously unimmunized persons</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2.1.1"></a><p></p>
<h4>Dose</h4>
<p class="First">Previously unvaccinated persons should receive 5 intramuscular doses (1 mL each) of Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine, one dose immediately after exposure (Day 0) and one dose 3, 7, 14, and 28 days later.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2.1.2"></a><p></p>
<h4>RIG</h4>
<p class="First"><span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> immune globulin (RIG) 20 IU/kg on Day 0 in conjunction with the first vaccine dose. If possible, the full calculated dose of RIG should be used to infiltrate the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span>(s). If it is not possible to do so, any remaining portion of the dose should be administered intramuscularly at a site different from the site used to administer the vaccine.</p>
<p>Because the antibody response following the recommended vaccination regimen with HDCV has been satisfactory, routine post-vaccination serologic testing is not recommended. Serologic testing is indicated in unusual circumstances, as when the patient is known to be immunosuppressed. Contact local or state health department or CDC for recommendations. (11) </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2.2"></a><p></p>
<h3>2. Post-exposure dosage for previously immunized persons</h3>
<p class="First">When an immunized person who was vaccinated using the recommended pre-exposure regimen or a prior post-exposure regimen with a cell culture vaccine or who had previously demonstrated <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> antibody is exposed to <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span>, that person should receive two intramuscular doses (1.0 mL each) of Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine, one dose immediately after the exposure and one dose 3 days later. RIG should not be given in these cases. </p>
<p>If the immune status of a previously vaccinated person who did not receive the recommended HDCV regimen is not known, full primary post-exposure antirabies treatment (RIG plus 5 doses of HDCV) may be necessary. In such cases, if antibody levels of greater than 1:5 dilution by a RFFIT can be demonstrated in a serum sample collected before vaccine is given, treatment can be discontinued after at least two doses of HDCV. (20)</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Imovax <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccine is supplied in a tamper evident unit dose box with: </p>
<dl>
<dt>-</dt>
<dd>One vial of freeze-dried vaccine containing a single dose (NDC 49281-248-58).</dd>
<dt>-</dt>
<dd>One sterile syringe containing diluent (NDC 49281-249-01). A separate plunger is provided for insertion and use.</dd>
<dt>-</dt>
<dd>One sterile disposable needle for reconstitution. </dd>
</dl>
<p>Packaged as NDC 49281-250-51.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-10.1"></a><p></p>
<h2>STORAGE</h2>
<p class="First">The freeze-dried vaccine is stable if stored in the refrigerator between 2°C and 8°C (35°F to 46°F). Do not freeze.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-11"></a><p></p>
<h1>REFERENCES</h1>
<dl>
<dt>1</dt>
<dd>Aoki FY, Tyrell DAJ, Hill LE. Immunogenicity and acceptability of a human diploid cell culture <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> vaccine in volunteers. The Lancet. 1975 Mar 22;1(7908):660-2.</dd>
<dt>2</dt>
<dd>Cox JH, Schneider LG. <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> immunization of humans against <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> by intradermal inoculation of human diploid cell culture vaccine. J Clin Microbiol. 1976 Feb;3(2):96-101.</dd>
<dt>3</dt>
<dd>Kuwert EK, Marcus I, Werner J, Iwand A, Thraenhart O. Some experiences with human diploid cell strain—(HDCS) <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> vaccine in pre- and postexposure vaccinated humans. Dev Biol Stand. 1978;40:79-88.</dd>
<dt>4</dt>
<dd>Ajjan N, Soulebot J-P, Stellmann C, Biron G, Charbonnier C, Triau R, Mérieux C. Résultats de la vaccination antirabique préventive par le vaccin inactivé concentré souche <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> PM/W138-1503-3M cultivés sur cellules diploïdes humaines. Dev Biol Stand. 1978;40:89-100.</dd>
<dt>5</dt>
<dd>Costy-Berger F. Vaccination antirabique préventive par du vaccin préparé sur cellules diploïdes humaines. Dev Biol Stand. 1978;40:101-4.</dd>
<dt>6</dt>
<dd>Bernard KW, Roberts MA, Sumner J, Winkler WG, Mallonee J, Baer GM, Chaney R. Human diploid cell <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> vaccine. JAMA. 1982 Feb 26;247(8):1138-42.</dd>
<dt>7</dt>
<dd>Bahmanyar M, Fayaz A, Nour-Salehi S, Mohammadi M, Koprowski H. Successful protection of humans exposed to <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. JAMA. 1976 Dec 13;236(24):2751-4.</dd>
<dt>8</dt>
<dd>CDC. Recommendations of the Immunization Practices Advisory Committee (ACIP). <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> Prevention--United States, 1984. MMWR. 1984 Jul 20;33(28):393-402, 407-8.</dd>
<dt>9</dt>
<dd>Shill M, Baynes RD, Miller SD. Fatal <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> <span class="product-label-link" type="condition" conceptid="378143" conceptname="Encephalitis">encephalitis</span> despite appropriate postexposure prophylaxis. N Engl J Med. 1987 May 14;316(20):1257-58.</dd>
<dt>10</dt>
<dd>CDC. Human <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> despite treatment with <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> immune globulin and human diploid cell <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> vaccine - Thailand. MMWR. 1987 Nov 27;36(46):759-60, 765.</dd>
<dt>11</dt>
<dd>Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumlertdacha B, Guerra M, et al. Human <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> prevention - United States 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR. 2008 May 23;57(RR-3):1-28.</dd>
<dt>12</dt>
<dd><span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccines: WHO position paper. Weekly epidemiological record. 2010 Aug 6;85(32):309-320. Available from: http://www.who.int/wer.</dd>
<dt>13</dt>
<dd>CDC. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Systemic allergic reactions</span> following immunization with human diploid cell <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> vaccine. MMWR. 1984 Apr 13;33(14):185-7.</dd>
<dt>14</dt>
<dd>Boe E, Nyland H. Guillain-Barré syndrome after vaccination with human diploid cell <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> vaccine. Scand J Infect Dis. 1980;12(3):231-2.</dd>
<dt>15</dt>
<dd>CDC. Adverse reactions to human diploid cell <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> vaccine. MMWR. 1980;29:609-10.</dd>
<dt>16</dt>
<dd>Bernard KW, Smith PW, Kader FJ, Moran MJ. Neuroparalytic illness and human diploid cell <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> vaccine. JAMA. 1982 Dec 17;248(23):3136-8.</dd>
<dt>17</dt>
<dd>Varner MW, McGuinness GA, Galask RP. <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> vaccination in pregnancy. Am J of Obstet Gynecol. 1982 Jul 15;143(6):717-8.</dd>
<dt>18</dt>
<dd>Cockshott WP, Thompson GT, Howlett LJ, Seely ET. Intramuscular or intralipomatous injections? N Eng J Med. 1982 Aug 5;307(6):356-8.</dd>
<dt>19</dt>
<dd>Baer GM, Fishbein DB. <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> postexposure prophylaxis. N Engl J Med. 1987;316:1270-72.</dd>
<dt>20</dt>
<dd>CDC. Recommendations of the Advisory Committee on Immunization Practices. Human <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> prevention-United States, 1999. MMWR. 1999;48(RR-1):1-21.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First">Product information as of April 2013</p>
<p>US Govt License #1724</p>
<p>Manufactured by:<br>Sanofi Pasteur SA<br>Lyon France  </p>
<p>Distributed by:<br>Sanofi Pasteur Inc.<br>Swiftwater PA 18370 USA<br>1-800-VACCINE (1-800-822-2463) </p>
<p>966660</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 1 mL Vial Label</h1>
<p class="First">NDC <span class="Bold">49281-248-58</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span><br>Vaccine<br>IMOVAX</span><span class="Sup">®</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">RABIES</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">RABIES</span><br>(HDCV)</p>
<p><span class="Bold">1<br>mL</span></p>
<p><span class="Bold">IM only</span></p>
<p><span class="Bold Italics">Rx only</span></p>
<p>Mfd by: <span class="Bold">Sanofi Pasteur SA</span></p>
<p>Lyon France US Govt Lic #1724<br>Dist by: Sanofi Pasteur Inc.<br>Swiftwater PA 18370 USA<br>1-800-VACCINE (1-800-822-2463)</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1 mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ba8d4e72-f452-4859-ae6f-3644b4b0a78c&amp;name=imovax-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 1 mL Syringe Label</h1>
<p class="First">NDC <span class="Bold">49281-249-01</span></p>
<p><span class="Bold">Sterile<br> Water,<br>diluent for<br>reconstitution</span><br>USP</p>
<p><span class="Bold">1<br> mL</span></p>
<p><span class="Bold Italics">Rx only</span></p>
<p>Contains no preservative</p>
<p><span class="Bold">Sanofi Pasteur</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1 mL Syringe Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ba8d4e72-f452-4859-ae6f-3644b4b0a78c&amp;name=imovax-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 1 mL Kit Carton</h1>
<p class="First">NDC <span class="Bold">49281-250-51</span><br>List No 2501</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> Vaccine<br>IMOVAX</span><span class="Sup">®</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">RABIES</span><br>PRE- AND POSTEXPOSURE<br>INTRAMUSCULAR IMMUNIZATION ONLY</span></p>
<p><span class="Bold">NOT FOR INTRADERMAL USE</span></p>
<p>Wistar <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">Rabies</span> Virus <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strain</span> PM-1503-3M-Grown in Human Diploid Cell<br>Cultures-Single Dose-Lyophilized Vaccine, Luer Syringe with Sterile water, diluent for reconstitution<br>USP, one needle for reconstitution.</p>
<p><span class="Bold">FOR INTRAMUSCULAR INJECTION</span></p>
<p><span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">RABIES</span><br>(HDCV)</p>
<p><span class="Bold">1 Dose<br>(1 mL)</span></p>
<p><span class="Bold Italics">Rx only</span></p>
<p><span class="Bold">SANOFI </span>PASTEUR</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1 mL Kit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ba8d4e72-f452-4859-ae6f-3644b4b0a78c&amp;name=imovax-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>IMOVAX RABIES 		
					</strong><br><span class="contentTableReg"><span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> virus <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> pm-1503-3m antigen (propiolactone inactivated) and water kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">VACCINE LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49281-250</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49281-250-51</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, SINGLE-USE </td>
<td class="formItem">1 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 SYRINGE </td>
<td class="formItem">1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>IMOVAX RABIES 		
					</strong><br><span class="contentTableReg"><span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> virus <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> pm-1503-3m antigen (propiolactone inactivated) injection, suspension</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49281-248</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong><span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">RABIES</span> VIRUS <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">STRAIN</span> PM-1503-3M ANTIGEN (PROPIOLACTONE INACTIVATED)</strong> (<span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">RABIES</span> VIRUS <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">STRAIN</span> PM-1503-3M ANTIGEN (PROPIOLACTONE INACTIVATED)) </td>
<td class="formItem"><span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">RABIES</span> VIRUS <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">STRAIN</span> PM-1503-3M ANTIGEN (PROPIOLACTONE INACTIVATED)</td>
<td class="formItem">2.5 [iU]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALBUMIN (HUMAN)</strong></td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>NEOMYCIN SULFATE</strong></td>
<td class="formItem">150 ug  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49281-248-58</td>
<td class="formItem">1 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103931</td>
<td class="formItem">09/30/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>WATER 		
					</strong><br><span class="contentTableReg">water injection, suspension</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49281-249</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49281-249-01</td>
<td class="formItem">1 mL in 1 SYRINGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103931</td>
<td class="formItem">09/30/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103931</td>
<td class="formItem">09/30/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sanofi Pasteur Inc.
							(086723285)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sanofi Pasteur SA</td>
<td class="formItem"></td>
<td class="formItem">381505171</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>4ac3daa6-590a-42d6-9143-78923c6b05f7</div>
<div>Set id: ba8d4e72-f452-4859-ae6f-3644b4b0a78c</div>
<div>Version: 6</div>
<div>Effective Time: 20130710</div>
</div>
</div> <div class="DistributorName">Sanofi Pasteur Inc.</div></p>
</body></html>
